NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Spyre Therapeutics, Inc. (SYRE) Stock Analysis

Spyre Therapeutics, Inc. (SYRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SYRE

$88.98

+$1.73 (+1.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SYRE with… →

SYRE Key Statistics

As of Sep 4, 2026
Trading
Open
$86.45
Previous Close
$87.25
Day's Range
84.68–89.18
52-Week Range
14.51–110.18
Volume
803.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.00
Valuation
Market Cap
$7.85B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.92
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$155.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
88.17M
1-Year Return
+423.72%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.31M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SYRE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+171.61%
2025+40.72%
2024+8.18%
2023+91.29%
2022−90.53%
2021−39.64%
2020+3.01%
2019+2.00%
2018+38.45%
2017+24.37%
2016 (partial year)−5.43%

As of September 4, 2026.

SYRE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$155.20M—
2024$0.00−$208.02M—
2023$886.00K−$338.79M−38238.1%
2022$2.33M−$83.82M−3598.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$219.56M−$155.20M—
2024$0.00—−$208.57M−$208.02M—
2023$886.00K—−$128.56M−$338.79M−38238.1%
2022$2.33M—−$84.78M−$83.82M−3598.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SYRE Valuation vs Biotechnology Median

Median of 656 stocks
MetricSYREBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Spyre Therapeutics, Inc. (SYRE) is capitalised at $7.85B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 125.

Over the past 52 weeks the price has ranged from $14.51 to $110.18. The most recent close on file for SYRE is $88.98, dated September 4, 2026. That is +$1.73 (+1.98%) against the previous close. The latest close sits 513.44% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $155.20M. Profit margin runs at 0%. Trailing earnings per share are −1.92.

Across the 4 fiscal years on file, revenue moves from $2.33M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 3. Daily returns over the trailing 10 years annualize to a volatility of 136.34%. Over the trailing twelve months the price has returned +423.72%. Across 10 years the annualized return works out at −5.47%.

Growth & Income

The record shows no dividend for SYRE.

2026 is still running; the price is +171.61% year to date. Across the complete calendar years on file, 2023 returned +91.29% and 2022 returned −90.53%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Spyre Therapeutics, Inc. (SYRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Spyre Therapeutics, Inc. SYRE $7.85B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Spyre Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Visit website →